Entry |
|
Symbol |
NFKB1, CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1, NF-kappaB, NF-kappabeta, NFKB-p105, NFKB-p50, NFkappaB
|
Name |
(RefSeq) nuclear factor kappa B subunit 1
|
KO |
K02580 | nuclear factor NF-kappa-B p105 subunit |
|
Organism |
|
Pathway |
hsa04613 | Neutrophil extracellular trap formation |
hsa04620 | Toll-like receptor signaling pathway |
hsa04621 | NOD-like receptor signaling pathway |
hsa04622 | RIG-I-like receptor signaling pathway |
hsa04625 | C-type lectin receptor signaling pathway |
hsa04658 | Th1 and Th2 cell differentiation |
hsa04660 | T cell receptor signaling pathway |
hsa04662 | B cell receptor signaling pathway |
hsa04920 | Adipocytokine signaling pathway |
hsa04932 | Non-alcoholic fatty liver disease |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications |
hsa05022 | Pathways of neurodegeneration - multiple diseases |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection |
hsa05130 | Pathogenic Escherichia coli infection |
hsa05163 | Human cytomegalovirus infection |
hsa05166 | Human T-cell leukemia virus 1 infection |
hsa05167 | Kaposi sarcoma-associated herpesvirus infection |
hsa05168 | Herpes simplex virus 1 infection |
hsa05170 | Human immunodeficiency virus 1 infection |
hsa05202 | Transcriptional misregulation in cancer |
hsa05207 | Chemical carcinogenesis - receptor activation |
hsa05208 | Chemical carcinogenesis - reactive oxygen species |
hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
hsa05418 | Fluid shear stress and atherosclerosis |
|
Network |
|
Element |
N00140 | FUS-DDIT3 fusion to NFKB-mediated transcription |
N00151 | TNF-NFKB signaling pathway |
N00171 | KSHV vFLIP to NFKB signaling pathway |
N00173 | KSHV K15 to TNF-NFKB signaling pathway |
N00174 | KSHV vFLIP to TNF-NFKB signaling pathway |
N00182 | IGF-IGFR-PI3K-NFKB signaling pathway |
N00265 | EBV LMP1 to NFKB signaling pathway |
N00269 | HCV core to TNF-NFKB signaling pathway |
N00389 | HCMV IE1-72 to transcription |
N00390 | EGF-EGFR-PI3K-NFKB signaling pathway |
N00398 | HCMV IE2-86 to TNF-NFKB signaling pathway |
N00399 | CCR2-GNB/G-PI3K-NFKB signaling pathway |
N00435 | TLR1/2/4-NFKB signaling pathway |
N00436 | HIV Tat to TLR2/4-NFKB signaling pathway |
N00437 | HIV Vpu to TLR2/4-NFKB signaling pathway |
N00441 | HIV gp120 to TNF-NFKB signaling pathway |
N00442 | HIV Nef to TNF-NFKB signaling pathway |
N00443 | HIV Vpr/Nef/Tat to TNF-NFKB signaling pathway |
N00504 | HTLV-1 Tax to NFKB signaling pathway |
N00550 | HBV HBeAg to TLR2/4-NFKB signaling pathway |
N00559 | LIGHT-HVEM-NFKB signaling pathway |
N00560 | HSV gD to HVEM-NFKB signaling pathway |
N00563 | TLR3-NFKB signaling pathway |
N00688 | RIG-I-NFKB signaling pathway |
N00689 | MV V/P/C to RIG-I-NFKB signaling pathway |
N00730 | IAV NS1 to RIG-I-like receptor signaling pathway |
N00932 | Escherichia NleH1 to TNF-NFKB signaling pathway |
N00940 | NOD-NFKB signaling pathway |
N00994 | AGE-RAGE signaling pathway |
N00996 | Mutation-caused aberrant Abeta to AGE-RAGE signaling pathway |
N01112 | Salmonella SopE/E2 to NOD-NFKB signaling pathway |
N01118 | Salmonella SpvD to TNF-NFKB signaling pathway |
N01306 | AngII-AT1R-NOX2 signaling pathway |
N01307 | SARS-CoV-2 S to AngII-AT1R-NOX2 signaling pathway |
N01339 | NNK/NNN to PI3K signaling pathway |
N01410 | Metals to NFKB signaling pathway |
N01411 | Metals to NFKB signaling pathway |
N01566 | TLR5-NFKB signaling pathway |
|
Disease |
H00088 | Common variable immunodeficiency |
|
Drug target |
|
Brite |
KEGG Orthology (KO) [BR:hsa00001]
09130 Environmental Information Processing
09132 Signal transduction
04010 MAPK signaling pathway
4790 (NFKB1)
04014 Ras signaling pathway
4790 (NFKB1)
04064 NF-kappa B signaling pathway
4790 (NFKB1)
04668 TNF signaling pathway
4790 (NFKB1)
04066 HIF-1 signaling pathway
4790 (NFKB1)
04071 Sphingolipid signaling pathway
4790 (NFKB1)
04024 cAMP signaling pathway
4790 (NFKB1)
04151 PI3K-Akt signaling pathway
4790 (NFKB1)
09140 Cellular Processes
09143 Cell growth and death
04210 Apoptosis
4790 (NFKB1)
04218 Cellular senescence
4790 (NFKB1)
09150 Organismal Systems
09151 Immune system
04613 Neutrophil extracellular trap formation
4790 (NFKB1)
04620 Toll-like receptor signaling pathway
4790 (NFKB1)
04621 NOD-like receptor signaling pathway
4790 (NFKB1)
04622 RIG-I-like receptor signaling pathway
4790 (NFKB1)
04623 Cytosolic DNA-sensing pathway
4790 (NFKB1)
04625 C-type lectin receptor signaling pathway
4790 (NFKB1)
04660 T cell receptor signaling pathway
4790 (NFKB1)
04658 Th1 and Th2 cell differentiation
4790 (NFKB1)
04659 Th17 cell differentiation
4790 (NFKB1)
04657 IL-17 signaling pathway
4790 (NFKB1)
04662 B cell receptor signaling pathway
4790 (NFKB1)
04062 Chemokine signaling pathway
4790 (NFKB1)
09152 Endocrine system
04920 Adipocytokine signaling pathway
4790 (NFKB1)
04917 Prolactin signaling pathway
4790 (NFKB1)
04926 Relaxin signaling pathway
4790 (NFKB1)
09156 Nervous system
04722 Neurotrophin signaling pathway
4790 (NFKB1)
09158 Development and regeneration
04380 Osteoclast differentiation
4790 (NFKB1)
09149 Aging
04211 Longevity regulating pathway
4790 (NFKB1)
09160 Human Diseases
09161 Cancer: overview
05200 Pathways in cancer
4790 (NFKB1)
05202 Transcriptional misregulation in cancer
4790 (NFKB1)
05206 MicroRNAs in cancer
4790 (NFKB1)
05207 Chemical carcinogenesis - receptor activation
4790 (NFKB1)
05208 Chemical carcinogenesis - reactive oxygen species
4790 (NFKB1)
05203 Viral carcinogenesis
4790 (NFKB1)
05235 PD-L1 expression and PD-1 checkpoint pathway in cancer
4790 (NFKB1)
09162 Cancer: specific types
05212 Pancreatic cancer
4790 (NFKB1)
05221 Acute myeloid leukemia
4790 (NFKB1)
05220 Chronic myeloid leukemia
4790 (NFKB1)
05215 Prostate cancer
4790 (NFKB1)
05222 Small cell lung cancer
4790 (NFKB1)
09172 Infectious disease: viral
05166 Human T-cell leukemia virus 1 infection
4790 (NFKB1)
05170 Human immunodeficiency virus 1 infection
4790 (NFKB1)
05161 Hepatitis B
4790 (NFKB1)
05160 Hepatitis C
4790 (NFKB1)
05171 Coronavirus disease - COVID-19
4790 (NFKB1)
05164 Influenza A
4790 (NFKB1)
05162 Measles
4790 (NFKB1)
05168 Herpes simplex virus 1 infection
4790 (NFKB1)
05163 Human cytomegalovirus infection
4790 (NFKB1)
05167 Kaposi sarcoma-associated herpesvirus infection
4790 (NFKB1)
05169 Epstein-Barr virus infection
4790 (NFKB1)
05165 Human papillomavirus infection
4790 (NFKB1)
09171 Infectious disease: bacterial
05120 Epithelial cell signaling in Helicobacter pylori infection
4790 (NFKB1)
05130 Pathogenic Escherichia coli infection
4790 (NFKB1)
05132 Salmonella infection
4790 (NFKB1)
05131 Shigellosis
4790 (NFKB1)
05135 Yersinia infection
4790 (NFKB1)
05133 Pertussis
4790 (NFKB1)
05134 Legionellosis
4790 (NFKB1)
05152 Tuberculosis
4790 (NFKB1)
09174 Infectious disease: parasitic
05146 Amoebiasis
4790 (NFKB1)
05145 Toxoplasmosis
4790 (NFKB1)
05140 Leishmaniasis
4790 (NFKB1)
05142 Chagas disease
4790 (NFKB1)
09163 Immune disease
05321 Inflammatory bowel disease
4790 (NFKB1)
09164 Neurodegenerative disease
05010 Alzheimer disease
4790 (NFKB1)
05022 Pathways of neurodegeneration - multiple diseases
4790 (NFKB1)
09165 Substance dependence
05030 Cocaine addiction
4790 (NFKB1)
09166 Cardiovascular disease
05417 Lipid and atherosclerosis
4790 (NFKB1)
05418 Fluid shear stress and atherosclerosis
4790 (NFKB1)
05415 Diabetic cardiomyopathy
4790 (NFKB1)
09167 Endocrine and metabolic disease
04936 Alcoholic liver disease
4790 (NFKB1)
04932 Non-alcoholic fatty liver disease
4790 (NFKB1)
04931 Insulin resistance
4790 (NFKB1)
04933 AGE-RAGE signaling pathway in diabetic complications
4790 (NFKB1)
09176 Drug resistance: antineoplastic
01523 Antifolate resistance
4790 (NFKB1)
09180 Brite Hierarchies
09182 Protein families: genetic information processing
03000 Transcription factors [BR:hsa03000]
4790 (NFKB1)
Transcription factors [BR:hsa03000]
Eukaryotic type
beta-Scaffold factors with minor groove contacts
RHR (Rel homology region) Rel/Ankyrin
4790 (NFKB1)
|
SSDB |
|
Motif |
|
Other DBs |
|
Structure |
|
LinkDB |
|
Position |
4:102501359..102617302
|
AA seq |
968 aa
MAEDDPYLGRPEQMFHLDPSLTHTIFNPEVFQPQMALPTDGPYLQILEQPKQRGFRFRYV
CEGPSHGGLPGASSEKNKKSYPQVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCED
GICTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACIRGYNPGLLVHPDLAYLQA
EGGGDRQLGDREKELIRQAALQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIY
DSKAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDF
SPTDVHRQFAIVFKTPKYKDINITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQ
RKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGGTGSTGPGYSFPHYGFPTYGGITFH
PGTTKSNAGMKHGTMDTESKKDPEGCDKSDDKNTVNLFGKVIETTEQDQEPSEATVGNGE
VTLTYATGTKEESAGVQDNLFLEKAMQLAKRHANALFDYAVTGDVKMLLAVQRHLTAVQD
ENGDSVLHLAIIHLHSQLVRDLLEVTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVED
LLRAGADLSLLDRLGNSVLHLAAKEGHDKVLSILLKHKKAALLLDHPNGDGLNAIHLAMM
SNSLPCLLLLVAAGADVNAQEQKSGRTALHLAVEHDNISLAGCLLLEGDAHVDSTTYDGT
TPLHIAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWENAGEDEGVVPGTTPLDMAT
SWQVFDILNGKPYEPEFTSDDLLAQGDMKQLAEDVKLQLYKLLEIPDPDKNWATLAQKLG
LGILNNAFRLSPAPSKTLMDNYEVSGGTVRELVEALRQMGYTEAIEVIQAASSPVKTTSQ
AHSLPLSPASTRQQIDELRDSDSVCDSGVETSFRKLSFTESLTSGASLLTLNKMPHDYGQ
EGPLEGKI |
NT seq |
2907 nt +upstreamnt +downstreamnt
atggcagaagatgatccatatttgggaaggcctgaacaaatgtttcatttggatccttct
ttgactcatacaatatttaatccagaagtatttcaaccacagatggcactgccaacagat
ggcccataccttcaaatattagagcaacctaaacagagaggatttcgtttccgttatgta
tgtgaaggcccatcccatggtggactacctggtgcctctagtgaaaagaacaagaagtct
taccctcaggtcaaaatctgcaactatgtgggaccagcaaaggttattgttcagttggtc
acaaatggaaaaaatatccacctgcatgcccacagcctggtgggaaaacactgtgaggat
gggatctgcactgtaactgctggacccaaggacatggtggtcggcttcgcaaacctgggt
atacttcatgtgacaaagaaaaaagtatttgaaacactggaagcacgaatgacagaggcg
tgtataaggggctataatcctggactcttggtgcaccctgaccttgcctatttgcaagca
gaaggtggaggggaccggcagctgggagatcgggaaaaagagctaatccgccaagcagct
ctgcagcagaccaaggagatggacctcagcgtggtgcggctcatgtttacagcttttctt
ccggatagcactggcagcttcacaaggcgcctggaacccgtggtatcagacgccatctat
gacagtaaagcccccaatgcatccaacttgaaaattgtaagaatggacaggacagctgga
tgtgtgactggaggggaggaaatttatcttctttgtgacaaagttcagaaagatgacatc
cagattcgattttatgaagaggaagaaaatggtggagtctgggaaggatttggagatttt
tcccccacagatgttcatagacaatttgccattgtcttcaaaactccaaagtataaagat
attaatattacaaaaccagcctctgtgtttgtccagcttcggaggaaatctgacttggaa
actagtgaaccaaaacctttcctctactatcctgaaatcaaagataaagaagaagtgcag
aggaaacgtcagaagctcatgcccaatttttcggatagtttcggcggtggtagtggtgct
ggagctggaggcggaggcatgtttggtagtggcggtggaggagggggcactggaagtaca
ggtccagggtatagcttcccacactatggatttcctacttatggtgggattactttccat
cctggaactactaaatctaatgctgggatgaagcatggaaccatggacactgaatctaaa
aaggaccctgaaggttgtgacaaaagtgatgacaaaaacactgtaaacctctttgggaaa
gttattgaaaccacagagcaagatcaggagcccagcgaggccaccgttgggaatggtgag
gtcactctaacgtatgcaacaggaacaaaagaagagagtgctggagttcaggataacctc
tttctagagaaggctatgcagcttgcaaagaggcatgccaatgcccttttcgactacgcg
gtgacaggagacgtgaagatgctgctggccgtccagcgccatctcactgctgtgcaggat
gagaatggggacagtgtcttacacttagcaatcatccaccttcattctcaacttgtgagg
gatctactagaagtcacatctggtttgatttctgatgacattatcaacatgagaaatgat
ctgtaccagacgcccttgcacttggcagtgatcactaagcaggaagatgtggtggaggat
ttgctgagggctggggccgacctgagccttctggaccgcttgggtaactctgttttgcac
ctagctgccaaagaaggacatgataaagttctcagtatcttactcaagcacaaaaaggca
gcactacttcttgaccaccccaacggggacggtctgaatgccattcatctagccatgatg
agcaatagcctgccatgtttgctgctgctggtggccgctggggctgacgtcaatgctcag
gagcagaagtccgggcgcacagcactgcacctggctgtggagcacgacaacatctcattg
gcaggctgcctgctcctggagggtgatgcccatgtggacagtactacctacgatggaacc
acacccctgcatatagcagctgggagagggtccaccaggctggcagctcttctcaaagca
gcaggagcagatcccctggtggagaactttgagcctctctatgacctggatgactcttgg
gaaaatgcaggagaggatgaaggagttgtgcctggaaccacgcctctagatatggccacc
agctggcaggtatttgacatattaaatgggaaaccatatgagccagagtttacatctgat
gatttactagcacaaggagacatgaaacagctggctgaagatgtgaagctgcagctgtat
aagttactagaaattcctgatccagacaaaaactgggctactctggcgcagaaattaggt
ctggggatacttaataatgccttccggctgagtcctgctccttccaaaacacttatggac
aactatgaggtctctgggggtacagtcagagagctggtggaggccctgagacaaatgggc
tacaccgaagcaattgaagtgatccaggcagcctccagcccagtgaagaccacctctcag
gcccactcgctgcctctctcgcctgcctccacaaggcagcaaatagacgagctccgagac
agtgacagtgtctgcgacagcggcgtggagacatccttccgcaaactcagctttaccgag
tctctgaccagtggtgcctcactgctaactctcaacaaaatgccccatgattatgggcag
gaaggacctctagaaggcaaaatttag |